The Dopamine D3 Receptor Knockout Mouse Mimics Aging-Related Changes in Autonomic Function and Cardiac Fibrosis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Johnson, Tracy L ^a   Tulis, David A ^a   Keeler, Benjamin E ^a   Virag, Jitka A ^a   Lust, Robert M ^a   Clemens, Stefan ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; DOPAMINE 3 RECEPTOR; GELATINASE A; GELATINASE B;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DYSFUNCTION; COLUMN ZYMOGRAPHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RATE; HYPERTENSION; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; SYSTOLIC BLOOD PRESSURE; TISSUE HOMOGENATE; WESTERN BLOTTING; WILD TYPE; ZYMOGRAPHY;

AGING; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; ECHOCARDIOGRAPHY; FIBROSIS; HEART RATE; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, DOPAMINE D3;

EID: 84883430624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074116     Document Type: Article

References (66)

1. Priebe HJ, (2000) The aged cardiovascular risk patient. Br J Anaesth 85: 763-778.
2. Torok T, Rudas L, (1997) Aging and cardiovascular autonomic regulation. Can J Anaesth 44: 677-678.
3. Laurent S, Boutouyrie P, Benetos A, (2002) Pathophysiology of hypertension in the elderly. Am J Geriatr Cardiol 11: 34-39.
4. de Leeuw PW, Birkenhager WH, (2001) The elderly hypertensive; cardiovascular and neurohormonal profile. Cardiovasc Drugs Ther 15: 263-267.
5. Novak V, Lipsitz LA (2004) Aging and the autonomic nervous system. In: Robertson D, Primer on the autonomic nervous system. Amsterdam: Elsevier. 191-193.
6. Dering MA, Santer RM, Watson AH, (1998) Age-related changes in the morphology of preganglionic neurons projecting to the paracervical ganglion of nulliparous and multiparous rats. Brain Res 780: 245-252.
7. Biernacka A, Frangogiannis NG, (2011) Aging and Cardiac Fibrosis. Aging Dis 2: 158-173.
8. Lakatta EG, Levy D, (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107: 346-354.
9. Goldberg LI, (1984) Dopamine receptors and hypertension. Physiologic and pharmacologic implications. Am J Med 77: 37-44.
10. Lundberg J, Lundberg D, Norgren L, Werner O, (1990) Dopamine counteracts hypertension during general anesthesia and hypotension during combined thoracic epidural anesthesia for abdominal aortic surgery. J Cardiothorac Anesth 4: 348-353.
11. Zeng C, Felder RA, Jose PA, (2006) A new approach for treatment of hypertension: modifying D1 dopamine receptor function. Cardiovasc Hematol Agents Med Chem 4: 369-377.
12. Felder RA, Eisner GM, Jose PA, (2000) D1 dopamine receptor signalling defect in spontaneous hypertension. Acta Physiol Scand 168: 245-250.
13. Tayebati SK, Lokhandwala MF, Amenta F, (2011) Dopamine and vascular dynamics control: present status and future perspectives. Curr Neurovasc Res 8: 246-257.
14. Banday AA, Lokhandwala MF, (2008) Dopamine receptors and hypertension. Curr Hypertens Rep 10: 268-275.
15. Zeng C, Armando I, Luo Y, Eisner GM, Felder RA, et al. (2008) Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol 294: H551-569.
16. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, et al. (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 102: 493-498.
17. Gomez Mde J, Rousseau G, Nadeau R, Berra R, Flores G, et al. (2002) Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart. Can J Physiol Pharmacol 80: 578-587.
18. Jose PA, Eisner GM, Felder RA, (2002) Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 11: 87-92.
19. Muhlbauer B, Kuster E, Luippold G, (2000) Dopamine D(3) receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiol Scand 168: 219-223.
20. Zeng C, Wang D, Asico LD, Welch WJ, Wilcox CS, et al. (2004) Aberrant D1 and D3 dopamine receptor transregulation in hypertension. Hypertension 43: 654-660.
21. Zeng C, Asico LD, Wang X, Hopfer U, Eisner GM, et al. (2003) Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension 41: 724-729.
22. Yu C, Yang Z, Ren H, Zhang Y, Han Y, et al. (2009) D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs. Am J Hypertens 22: 877-883.
23. Jose PA, Soares-da-Silva P, Eisner GM, Felder RA, (2010) Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. Biochim Biophys Acta 1802: 1259-1267.
24. Villar VA, Jones JE, Armando I, Palmes-Saloma C, Yu P, et al. (2009) G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function of the dopamine D3 receptor. J Biol Chem 284: 21425-21434.
25. Zhang Y, Takagawa J, Sievers RE, Khan MF, Viswanathan MN, et al. (2007) Validation of the wall motion score and myocardial performance indexes as novel techniques to assess cardiac function in mice after myocardial infarction. Am J Physiol Heart Circ Physiol 292: H1187-1192.
26. Dries JL, Kent SD, Virag JA, (2011) Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. J Physiol 589: 1725-1740.
27. Virag JA, Dries JL, Easton PR, Friesland AM, DeAntonio JH, et al. (2010) Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. Am J Physiol Heart Circ Physiol 298: H1088-1095.
28. Lopez-De Leon A, Rojkind M, (1985) A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33: 737-743.
29. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, et al. (2007) Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 171: 1431-1440.
30. Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, et al. (2001) Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 104: 2710-2715.
31. Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, et al. (2011) The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther 339: 394-402.
32. Mukhopadhyay S, Tulis DA, (2007) Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem 5: 311-318.
33. Tulis DA, (2008) Novel therapies for cyclic GMP control of vascular smooth muscle growth. Am J Ther 15: 551-564.
34. Frangogiannis NG, (2012) Matricellular proteins in cardiac adaptation and disease. Physiol Rev 92: 635-688.
35. de Souza RR, (2002) Aging of myocardial collagen. Biogerontology 3: 325-335.
36. Spinale FG, (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87: 1285-1342.
37. Morley ME, Riches K, Peers C, Porter KE, (2007) Hypoxic inhibition of human cardiac fibroblast invasion and MMP-2 activation may impair adaptive myocardial remodelling. Biochem Soc Trans 35: 905-907.
38. Vassiliadis E, Veidal SS, Barascuk N, Mullick JB, Clausen RE, et al. (2011) Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol 11: 6.
39. Hartman RP, Kawashima A, King BF Jr, (2003) Evaluation of renal causes of hypertension. Radiologic clinics of North America 41: 909-929.
40. Freel EM, Connell JM, (2004) Mechanisms of hypertension: the expanding role of aldosterone. Journal of the American Society of Nephrology: JASN 15: 1993-2001.
41. Julius S, Pascual AV, London R, (1971) Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 44: 413-418.
42. Safar ME, Boudier HS, (2005) Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension 46: 205-209.
43. Julius S, (1988) Transition from high cardiac output to elevated vascular resistance in hypertension. American heart journal 116: 600-606.
44. Palatini P, Julius S, (2009) The role of cardiac autonomic function in hypertension and cardiovascular disease. Current hypertension reports 11: 199-205.
45. von Borell E, Langbein J, Despres G, Hansen S, Leterrier C, et al. (2007) Heart rate variability as a measure of autonomic regulation of cardiac activity for assessing stress and welfare in farm animals-a review. Physiol Behav 92: 293-316.
46. Parati G, Frattola A, Omboni S, Mancia G, Di Rienzo M, (1996) Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. Clin Sci (Lond) 91Suppl: 129-132.
47. Manconi M, Ferri R, Zucconi M, Clemens S, Rundo F, et al. (2011) Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep. Sleep Med 12: 47-55.
48. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 93: 1945-1949.
49. Clemens S, Rye D, Hochman S, (2006) Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67: 125-130.
50. Innes KE, Selfe TK, Agarwal P, (2012) Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: A systematic review. Sleep Med Rev 16: 309-339.
51. Schlesinger I, Erikh I, Avizohar O, Sprecher E, Yarnitsky D, (2009) Cardiovascular risk factors in restless legs syndrome. Mov Disord 24: 1587-1592.
52. Manconi M, Ferri R, Zucconi M, Clemens S, Giarolli L, et al. (2011) Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome. Neurology 77: 110-117.
53. Manconi M, Ferri R, Zucconi M, Clemens S, Rundo F, et al. (2010) Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep. Sleep Med.
54. Lakatta EG, (2002) Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 7: 29-49.
55. Qiu H, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, et al. (2010) Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. Circ Res 107: 615-619.
56. Horn MA, Graham HK, Richards MA, Clarke JD, Greensmith DJ, et al. (2012) Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J Mol Cell Cardiol 53: 82-90.
57. Latini R, Masson S, Jeremic G, Luvara G, Fiordaliso F, et al. (1998) Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 31: 601-608.
58. Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, et al. (2011) Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Mod Rheumatol 21: 260-266.
59. Hardwick JC, Southerland EM, Girasole AE, Ryan SE, Negrotto S, et al. (2012) Remodeling of intrinsic cardiac neurons: effects of beta-adrenergic receptor blockade in guinea pig models of chronic heart disease. Am J Physiol Regul Integr Comp Physiol 303: R950-958.
60. McCain ML, Parker KK, (2011) Mechanotransduction: the role of mechanical stress, myocyte shape, and cytoskeletal architecture on cardiac function. Pflugers Arch 462: 89-104.
61. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, et al. (2008) Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 118: 1380-1389.
62. Giorelli M, Livrea P, Trojano M, (2005) Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J Interferon Cytokine Res 25: 395-406.
63. Chiao YA, Dai Q, Zhang J, Lin J, Lopez EF, et al. (2011) Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet 4: 455-462.
64. Chiao YA, Ramirez TA, Zamilpa R, Okoronkwo SM, Dai Q, et al. (2012) Matrix Metalloproteinase-9 Deletion Attenuates Myocardial Fibrosis and Diastolic Dysfunction in Aging Mice. Cardiovasc Res.
65. Lekakis JP, Zakopoulos NA, Protogerou AD, Kotsis VT, Papaioannou TG, et al. (2004) Cardiac hypertrophy in hypertension: relation to 24-h blood pressure profile and arterial stiffness. Int J Cardiol 97: 29-33.
66. Chen-Izu Y, Chen L, Banyasz T, McCulle SL, Norton B, et al. (2007) Hypertension-induced remodeling of cardiac excitation-contraction coupling in ventricular myocytes occurs prior to hypertrophy development. Am J Physiol Heart Circ Physiol 293: H3301-3310.